喹硫平联合脑电生物反馈治疗以阴性症状为主的精神分裂症的临床疗效

Clinical efficacy of Quetiapine combined with EEG biofeedback in treatment of schizophrenia mainly with negative symptoms

目的:分析以阴性症状为主的精神分裂症患者行喹硫平联合脑电生物反馈治疗的临床疗效。方法:收集60例以阴性症状为主的精神分裂症患者,根据治疗方法不同分为观察组和对照组,每组30例。观察组行喹硫平联合脑电生物反馈治疗,对照组行喹硫平治疗,采用PANSS量表进行效果评定,采用不良反应症状量表(TESS)进行不良反应评定。结果:观察组患者PANSS量表评分在第4、8周末与对照组比较明显降低(P<0.05),观察组的不良反应发生率为23.33%,低于对照组的30.00%,两组比较差异无统计学意义(P>0.05)。结论:以阴性症状为主的精神分裂症患者采用喹硫平联合脑电生物反馈治疗,临床效果显著,具有较高的安全性。

Objective： To analyze clinical efficacy of Quetiapine combined with EEG biofeedback in treatment of schizophrenia mainly with negative symptoms.Methods： 60 schizophrenia patients mainly with negative symptoms were collected and divided into 2 groups according to the treatment methods （30 cases in each group）.The study group was treated with Quetiapine combined with EEG biofeedback,while the control group was treated with Quetiapine.The positive and negative symptom scale （PANSS） was used to assess the effects,and the adverse reactions were evaluated by using the treatment emergent symptom scale （TESS）.Results： The PANSS scores of the study group were significantly lower than those of the control group 4 and 8 weeks after the treatment （P〈0.05）.The adverse reaction rate of the study group （23.33%） was lower than that of the control group （30.00%）,and the difference between the two groups was not statistically significant （P〉 0.05）.Conclusions： Quetiapine combined with EEG biofeedback in the treatment of schizophrenia mainly with negative symptoms is significantly with a high safety.